Statin use for the prevention of seizure and epilepsy in the patients at risk: A systematic review and meta-analysis of cohort studies

2021 ◽  
pp. 106652
Author(s):  
Yu Guo ◽  
Ling-Hong Zhu ◽  
Kai Zhao ◽  
Xin-Mei Guo ◽  
Ming-Fei Yang
2014 ◽  
Vol 12 (5) ◽  
pp. 736-747 ◽  
Author(s):  
P. P. Wisman ◽  
M. Roest ◽  
F. W. Asselbergs ◽  
P. G. de Groot ◽  
F. L. Moll ◽  
...  

2006 ◽  
Vol 27 (22) ◽  
pp. 2667-2674 ◽  
Author(s):  
G. G.L. Biondi-Zoccai ◽  
M. Lotrionte ◽  
P. Agostoni ◽  
A. Abbate ◽  
M. Fusaro ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e045978
Author(s):  
Jordi Martínez-Soldevila ◽  
Roland Pastells-Peiró ◽  
Carolina Climent-Sanz ◽  
Gerard Piñol-Ripoll ◽  
Mariona Rocaspana-García ◽  
...  

IntroductionThe gradual changes over the decades in the longevity and ageing of European society as a whole can be directly related to the prolonged decline in the birth rate and increase in the life expectancy. According to the WHO, there is an increased risk of dementia or other cognitive disorders as the population ages, which have a major impact on public health. Mild cognitive impairment (MCI) is described as a greater than expected cognitive decline for an individual’s age and level of education, but that does not significantly interfere with activities of daily living. Patients with MCI exhibit a higher risk of dementia compared with others in the same age group, but without a cognitive decline, have impaired walking and a 50% greater risk of falling.The urban lifestyle and advent of smartphones, mobility and immediate access to all information via the internet, including health information, has led to a totally disruptive change in most general aspects.This systematic review protocol is aimed at evaluating the effectiveness of technology-based interventions in the detection, prevention, monitoring and treatment of patients at risk or diagnosed with MCI.Methods and analysisThis review protocol follows the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols reporting guidelines. The search will be performed on MEDLINE (PubMed), CENTRAL, CINAHL Plus, ISI Web of Science and Scopus databases from 2010 to 2020. Studies of interventions either randomised clinical trials or pre–post non-randomised quasi-experimental designs, published in English and Spanish will be included. Articles that provide relevant information on the use of technology and its effectiveness in interventions that assess improvements in early detection, prevention, follow-up and treatment of the patients at risk or diagnosed with MCI will be included.Ethics and disseminationEthics committee approval not required. The results will be disseminated in publications and congresses.


2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Hayden F. Atkinson ◽  
Trevor B. Birmingham ◽  
Rebecca F. Moyer ◽  
Daniel Yacoub ◽  
Lauren E. Kanko ◽  
...  

2018 ◽  
Vol 13 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Umair Iqbal ◽  
Brittany B. Dennis ◽  
Andrew A. Li ◽  
George Cholankeril ◽  
Donghee Kim ◽  
...  

2019 ◽  
Vol 39 (4) ◽  
pp. 306-314 ◽  
Author(s):  
Matthew R. Lozier ◽  
Alexandra M. Sanchez ◽  
John J. Lee ◽  
Leonardo J. Tamariz ◽  
Gabriel A. Valle

Debates exist regarding the merit of starting one dialysis modality over the other for improved cardiovascular outcomes. Five previously published prospective and retrospective cohort studies have reported inconsistent conclusions on this topic. The aim of this systematic review and meta-analysis is to evaluate the influence initiation of hemodialysis (HD) vs peritoneal dialysis (PD) may have on the relative risk (RR) of subsequent development of adverse cardiovascular events (ACVE) in patients with end-stage renal disease (ESRD). Of the 518 records identified, 5 cohort studies, assessing a total of 47,062 patients were included in the meta-analysis. With regard to the subsequent development of ACVE following initiation on the different dialysis modalities, the pooled RR was found to be non-significant. Peritoneal dialysis is a suitable and cost-effective alternative to HD for ESRD patients at risk of cardiovascular disease.


Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Emily K Acton ◽  
Ossama Khazaal ◽  
Allison W Willis ◽  
Sean Hennessy ◽  
Michael A Gelfand ◽  
...  

Introduction: Cerebrovascular disease is the leading cause of seizures and incident epilepsy of known etiology in older adults. As prophylactic use of antiepileptic drugs remains controversial, statins have garnered attention as an alternate preventive strategy due to pleiotropic effects, beyond lipid-lowering, which may include neuroprotective and anti-epileptogenic properties. Our objective was to assess the current evidence on statin use for prevention of post-stroke seizure and post-stroke epilepsy (PSE). Methods: We conducted a systematic review following PRISMA guidelines. Pubmed and Embase were searched from database inception to May 2019 for English-language, full-text experimental, observational analytic, or systematic reviews/meta-analytic studies examining the association between statin use in adults and development of early-onset seizures (ES; seizures ≤7 days after stroke) or PSE. Pooled analyses were based on random-effects models using the inverse-variance method. Results: Of 157 citations, 154 were excluded due to duplication or ineligibility, yielding 3 cohort studies from East Asia. Two studies reported on outcomes of ischemic stroke and 1 on hemorrhagic stroke. Only 1 study reported on ES, finding a significantly reduced risk following post-stroke statin use (OR 0.35, CI 0.20-0.60). Two studies reported on pre-stroke statin use, with findings demonstrating a lack of association with PSE (pooled OR 1.17, CI 0.93-1.48; Figure 1.1). However, post-stroke statin use was associated with less PSE (pooled OR 0.61, CI 0.50-0.74), without evidence of heterogeneity (Figure 1.2). Conclusions: Systematic review and meta-analysis of 3 high-quality cohort studies suggests post-stroke, but not pre-stroke, statin use may be associated with reduced risk of PSE. Further research is warranted to verify if these findings are replicable in other populations, as well as to explore the influence of timing and duration of statin use on outcomes.


Sign in / Sign up

Export Citation Format

Share Document